Before PS overlap weighting, patients initiating GLP-1-RAs had higher rates of diabetic neuropathy and obesity, as well as higher prevalence of insulin, sodium-glucose cotransporter-2 inhibitor, and biologic prescriptions. The gene discussed is SLC5A2; the disease is obesity disorder.